# NCT06885281 (NCT06885281)

> A Study of ZL-1310 in Participants With Selected Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06885281
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Zai Lab (Shanghai) Co., Ltd.
- Conditions: Solid Tumors
- Interventions: ZL-1310
- Enrollment: 166
- Primary outcome: Incidence of Treatment Emergent Adverse-Events in Phase 1b
- Primary outcome: Incidence of Serious Adverse Events in Phase 1b
- Primary outcome: Evaluate antitumor activity of ZL-1310 as a single agent in Phase 2

## Indexed commentary on NCT06885281 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct06885281